Docetaxel chemotherapy is commonly used after next generation hormonal agents (NHA; e.g., abiraterone and enzalutamide) for the treatment of metastatic castration resistant prostate cancer (mCRPC), but information on outcomes associated with docetaxel in this setting is lacking.